Literature DB >> 14567026

Peritonectomy procedures.

Paul H Sugarbaker1.   

Abstract

Treatment of peritoneal surface malignancy requires a combined approach that uses peritonectomy procedures and perioperative intraperitoneal chemotherapy. In addition, knowledgeable patient selection is mandatory. This article illustrates the visceral and parietal peritonectomy procedures that one must use in an attempt to resect all visible evidence of disease. Complete cytoreduction is essential for treatment of peritoneal surface malignancy to result in long-term survival. Several different procedures are required in a single surgical event that may require 8-12 hours. Their use depends on the distribution and extent of invasion of the malignancy disseminated within the peritoneal space.

Entities:  

Mesh:

Year:  2003        PMID: 14567026     DOI: 10.1016/s1055-3207(03)00048-6

Source DB:  PubMed          Journal:  Surg Oncol Clin N Am        ISSN: 1055-3207            Impact factor:   3.495


  42 in total

1.  Clinical outcomes according to primary treatment in gastric cancer patients with peritoneal seeding.

Authors:  Jung Min Bae; Kyoung Joon Yeo; Se Won Kim; Sang Woon Kim; Sun Kyo Song
Journal:  J Gastric Cancer       Date:  2011-09-29       Impact factor: 3.720

2.  Cellularity in low-grade Pseudomyxoma peritonei impacts recurrence-free survival following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

Authors:  Philipp Horvath; Can Yurttas; Philipp Birk; Florian Struller; Alfred Königsrainer
Journal:  Langenbecks Arch Surg       Date:  2018-12-01       Impact factor: 3.445

Review 3.  Peritoneal carcinomatosis of colorectal origin: incidence and current treatment strategies.

Authors:  Manuel J Koppe; Otto C Boerman; Wim J G Oyen; Robert P Bleichrodt
Journal:  Ann Surg       Date:  2006-02       Impact factor: 12.969

4.  Systemic exposure of the parent drug oxaliplatin during hyperthermic intraperitoneal perfusion.

Authors:  H Mahteme; I Wallin; B Glimelius; L Påhlman; H Ehrsson
Journal:  Eur J Clin Pharmacol       Date:  2008-06-18       Impact factor: 2.953

5.  Morbidity, mortality, and oncological outcomes of 401 consecutive cytoreductive procedures with hyperthermic intraperitoneal chemotherapy (HIPEC).

Authors:  Mariangela Desantis; Jean-Louis Bernard; Vincent Casanova; Marianne Cegarra-Escolano; Emmanuel Benizri; Amine M Rahili; Daniel Benchimol; Jean-Marc Bereder
Journal:  Langenbecks Arch Surg       Date:  2014-10-16       Impact factor: 3.445

6.  A randomized trial of goal directed vs. standard fluid therapy in cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.

Authors:  Luca Colantonio; Claudia Claroni; Luana Fabrizi; Maria Elena Marcelli; Maria Sofra; Diana Giannarelli; Alfredo Garofalo; Ester Forastiere
Journal:  J Gastrointest Surg       Date:  2015-01-17       Impact factor: 3.452

7.  Normothermic and Hyperthermic Intraperitoneal Chemoperfusions with Cisplatin to Treat Advanced Ovarian Cancer in Experimental Settings.

Authors:  G S Kireeva; V G Bespalov; O A Belyaeva; K Y Senchik; A N Stukov; G I Gafton; K D Guseynov; A M Belyaev
Journal:  Pathol Oncol Res       Date:  2017-01-23       Impact factor: 3.201

Review 8.  Extravascular use of drug-eluting beads: a promising approach in compartment-based tumor therapy.

Authors:  Simon Binder; Andrew L Lewis; J-Matthias Löhr; Michael Keese
Journal:  World J Gastroenterol       Date:  2013-11-21       Impact factor: 5.742

9.  An Unusual Case of Peritoneal Carcinomatosis.

Authors:  Stijn Hillewaere; Linde Stessens; Kurt Van der Speeten
Journal:  Case Rep Oncol       Date:  2010-09-09

Review 10.  Using pharmacologic data to plan clinical treatments for patients with peritoneal surface malignancy.

Authors:  Kurt Van der Speeten; Oswald Anthony Stuart; Paul H Sugarbaker
Journal:  Curr Drug Discov Technol       Date:  2009-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.